Incompetence arrives on The Most Inopportune Day
I can't believe SVA issue the Globe & Mail article as a NR today.
Stock opens $2.21 and Target $2.50 once again knocks the wind out of the sails.
We had such an opportunity to get the stock towards $3.00 and blew it.
Common Sense should tell Dr Loe not to recommend SVA to The Globe & Mail
until after the Interim Clinical Trial Results are released.
He should have arranged to have it coincide with the following day after results.
It is so easy to be organized if one uses common sense.
To-day's Timing could not be worse.
Dr Loe owes SVA Big Time. I am grateful we are his Top Pick, but get a new target.